Bayer HealthCare Pharmaceuticals has decided to discontinue marketing of Viadur (leuprolide acetate implant). This action was taken due to a diminished market demand and growing manufacturing costs and is not the result of safety or efficacy issues. Bayer will fulfill orders until current supplies are depleted, which is expected by the end of April 2008. Viadur is indicated to manage the symptoms associated with advanced prostate cancer, including pain, urinary problems and other symptoms typical of the disease.

For more information call (800)288-8370 or visit